A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ARV-471 (PF-07850327)|COMBINATION_PRODUCT: Palbociclib|DRUG: Letrozole|COMBINATION_PRODUCT: Palbociclib
Sponsor: Pfizer
Collaborators: Arvinas Estrogen Receptor, Inc.